Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Leukemia & Lymphoma|December 24, 1997
P-glycoprotein expression in de novo acute myeloid leukemiaG Del Poeta, A Venditti, G Aronica, et al.
Drugs of Today (Barcelona, Spain : 1998)|June 3, 2016
Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemiaG Del Poeta, M Postorino, L Pupo, et al.
Leukemia Research|June 22, 1999
P-glycoprotein and terminal transferase expression identify prognostic subsets within cytogenetic risk classes in acute myeloid leukemiaG Del Poeta, A Venditti, R Stasi, et al.
Leukemia|October 25, 2003
Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantationA Venditti, L Maurillo, F Buccisano, et al.
Leukemia|July 14, 2006
The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemiaF Buccisano, L Maurillo, V Gattei, et al.
Blood|January 15, 1997
Minimally differentiated acute myeloid leukemia (AML-M0): comparison of 25 cases with other French-American-British subtypesA Venditti, G Del Poeta, F Buccisano, et al.
Bone Marrow Transplantation|November 11, 1999
Enumeration of CD34+ hematopoietic progenitor cells for clinical transplantation: comparison of three different methodsA Venditti, A Battaglia, G Del Poeta, et al.
Leukemia Research|February 21, 2023
Comparison between azacitidine and decitabine as front-line therapy in elderly acute myeloid leukemia patients not eligible for intensive chemotherapyL Maurillo, A Spagnoli, A Candoni, et al.
Annals of Hematology|April 15, 2015
Minimal residual disease negativity in elderly patients with acute myeloid leukemia may indicate different postremission strategies than in younger patientsF Buccisano, L Maurillo, A Piciocchi, et al.
Leukemia Research|June 30, 2015
Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromesG Caocci, M T Voso, E Angelucci, et al.
Pageof 3